- Home
- ATOS vs TAYD Comparison
ATOS vs TAYD Comparison
Compare ATOS & TAYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- TAYD
- Stock Information
- Founded
- ATOS 2009
- TAYD 1955
- Country
- ATOS United States
- TAYD United States
- Employees
- ATOS N/A
- TAYD N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- TAYD Industrial Machinery/Components
- Sector
- ATOS Health Care
- TAYD Industrials
- Exchange
- ATOS Nasdaq
- TAYD Nasdaq
- Market Cap
- ATOS 107.2M
- TAYD 114.6M
- IPO Year
- ATOS 2012
- TAYD N/A
- Fundamental
- Price
- ATOS $0.94
- TAYD $45.88
- Analyst Decision
- ATOS Strong Buy
- TAYD
- Analyst Count
- ATOS 3
- TAYD 0
- Target Price
- ATOS $6.17
- TAYD N/A
- AVG Volume (30 Days)
- ATOS 1.5M
- TAYD 32.2K
- Earning Date
- ATOS 08-11-2025
- TAYD 08-14-2025
- Dividend Yield
- ATOS N/A
- TAYD N/A
- EPS Growth
- ATOS N/A
- TAYD 1.48
- EPS
- ATOS N/A
- TAYD 2.50
- Revenue
- ATOS N/A
- TAYD $42,796,782.00
- Revenue This Year
- ATOS N/A
- TAYD $15.06
- Revenue Next Year
- ATOS N/A
- TAYD $8.37
- P/E Ratio
- ATOS N/A
- TAYD $18.54
- Revenue Growth
- ATOS N/A
- TAYD N/A
- 52 Week Low
- ATOS $0.55
- TAYD $29.50
- 52 Week High
- ATOS $1.66
- TAYD $64.50
- Technical
- Relative Strength Index (RSI)
- ATOS 58.44
- TAYD 66.36
- Support Level
- ATOS $0.81
- TAYD $43.92
- Resistance Level
- ATOS $0.88
- TAYD $45.76
- Average True Range (ATR)
- ATOS 0.05
- TAYD 2.47
- MACD
- ATOS 0.01
- TAYD 0.24
- Stochastic Oscillator
- ATOS 84.07
- TAYD 90.11
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About TAYD Taylor Devices Inc.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.